141 related articles for article (PubMed ID: 10365829)
21. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis.
Moore PS; Orlandini S; Zamboni G; Capelli P; Rigaud G; Falconi M; Bassi C; Lemoine NR; Scarpa A
Br J Cancer; 2001 Jan; 84(2):253-62. PubMed ID: 11161385
[TBL] [Abstract][Full Text] [Related]
23. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma.
Duell EJ; Casella DP; Burk RD; Kelsey KT; Holly EA
Cancer Epidemiol Biomarkers Prev; 2006 Apr; 15(4):726-31. PubMed ID: 16614115
[TBL] [Abstract][Full Text] [Related]
24. Neoplasms of the ampulla of vater with concurrent pancreatic intraductal neoplasia: a histological and molecular study.
Agoff SN; Crispin DA; Bronner MP; Dail DH; Hawes SE; Haggitt RC
Mod Pathol; 2001 Mar; 14(3):139-46. PubMed ID: 11266517
[TBL] [Abstract][Full Text] [Related]
25. Limitations in improving detection of pancreatic adenocarcinoma.
Mendieta Zerón H; García Flores JR; Romero Prieto ML
Future Oncol; 2009 Jun; 5(5):657-68. PubMed ID: 19519205
[TBL] [Abstract][Full Text] [Related]
26. Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer.
Salek C; Minarikova P; Benesova L; Nosek V; Strnad R; Zavoral M; Minarik M
Anticancer Res; 2009 May; 29(5):1803-10. PubMed ID: 19443408
[TBL] [Abstract][Full Text] [Related]
27. [New molecular targets in pancreatic cancer].
Torrisani J; Bournet B; Cordelier P; Buscail L
Bull Cancer; 2008 May; 95(5):503-12. PubMed ID: 18541514
[TBL] [Abstract][Full Text] [Related]
28. Application of molecular biology studies to gene therapy treatment strategies.
Gustin A; Pederson L; Miller R; Chan C; Vickers SM
World J Surg; 2002 Jul; 26(7):854-60. PubMed ID: 11960211
[TBL] [Abstract][Full Text] [Related]
29. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.
Slebos RJ; Hoppin JA; Tolbert PE; Holly EA; Brock JW; Zhang RH; Bracci PM; Foley J; Stockton P; McGregor LM; Flake GP; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1223-32. PubMed ID: 11097231
[TBL] [Abstract][Full Text] [Related]
30. [2000 Standards, Options and Recommendations for prognostic value of oncogenes and tumor suppressor genes in non small cell lung cancer].
Bréchot JM; Molina T; Theobald S; Depierre A; Lagrange JL; Astoul P; Baldeyrou P; Bardet E; Bazelly B; Breton JL; Douillard JY; Grivaux M; Jacoulet P; Khalil A; Lemarié E; Martinet Y; Massard G; Milleron B; Moro-Sibilot D; Paesmans M; Pujol JL; Quoix AE; Ranfaing E; Rivière A; Sancho-Garnier H; Souquet PJ; Spaeth D; Stcebner-Delbarre A;
Bull Cancer; 2002 Oct; 89(10):857-67. PubMed ID: 12441277
[TBL] [Abstract][Full Text] [Related]
31. Recent discoveries in cancer genetics of exocrine pancreatic neoplasia.
Hahn SA; Schmiegel WH
Digestion; 1998 Aug; 59(5):493-501. PubMed ID: 9705534
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of synuclein-gamma in pancreatic adenocarcinoma.
Li Z; Sclabas GM; Peng B; Hess KR; Abbruzzese JL; Evans DB; Chiao PJ
Cancer; 2004 Jul; 101(1):58-65. PubMed ID: 15221989
[TBL] [Abstract][Full Text] [Related]
33. Characterization of FAMPAC, a newly identified human pancreatic carcinoma cell line with a hereditary background.
Eisold S; Ryschich E; Linnebacher M; Giese T; Nauheimer D; Wild A; Bartsch DK; Büchler MW; Schmidt J
Cancer; 2004 May; 100(9):1978-86. PubMed ID: 15112280
[TBL] [Abstract][Full Text] [Related]
34. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M
Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039
[TBL] [Abstract][Full Text] [Related]
35. Genetics of pancreatic cancer. From genes to families.
Hruban RH; Petersen GM; Ha PK; Kern SE
Surg Oncol Clin N Am; 1998 Jan; 7(1):1-23. PubMed ID: 9443984
[TBL] [Abstract][Full Text] [Related]
36. Are there several colorectal cancers? Epidemiological data.
Bonithon-Kopp C; Benhamiche AM
Eur J Cancer Prev; 1999 Dec; 8 Suppl 1():S3-12. PubMed ID: 10772412
[TBL] [Abstract][Full Text] [Related]
37. Role of hypermethylation on carcinogenesis in the pancreas.
Kuroki T; Tajima Y; Kanematsu T
Surg Today; 2004; 34(12):981-6. PubMed ID: 15580378
[TBL] [Abstract][Full Text] [Related]
38. Relationship between K-ras mutation and the expression of p21WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma.
Hermanová M; Lukás Z; Kroupová I; Kleibl Z; Novotný J; Nenutil R; Pazourková M; Brázdil J; Kren L; Díte P
Neoplasma; 2003; 50(5):319-25. PubMed ID: 14628083
[TBL] [Abstract][Full Text] [Related]
39. K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis.
van Heek T; Rader AE; Offerhaus GJ; McCarthy DM; Goggins M; Hruban RH; Wilentz RE
Am J Clin Pathol; 2002 May; 117(5):755-65. PubMed ID: 12090425
[TBL] [Abstract][Full Text] [Related]
40. Caveolin-1: a marker for pancreatic cancer diagnosis.
Tanase CP
Expert Rev Mol Diagn; 2008 Jul; 8(4):395-404. PubMed ID: 18598222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
